6 yen to php

Tom Brady Is Predicting A Big Rematch In The NFL Playoffs This YearSOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment of neurodegenerative diseases, today announced results from the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD). Treatment with AL002 resulted in sustained target engagement and pharmacodynamic responses indicative of microglial activation. However, AL002 failed to meet the primary endpoint of slowing of Alzheimer's clinical progression as measured by the Clinical Dementia Rating Sum of Boxes (CDR ® -SB), and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints. Similarly, there were no significant effects on Alzheimer's fluid biomarkers favoring AL002, and amyloid PET imaging demonstrated no treatment-related reduction of brain amyloid levels. As previously reported, MRI changes resembling amyloid-related imaging abnormalities (ARIA) and infusion-related reactions were observed in INVOKE-2. The instances of ARIA were primarily seen in participants treated with AL002. "We, at Alector, recognize the importance of advancing therapeutics to treat Alzheimer's disease and remain committed in our mission to develop safe and effective treatments for the millions of people worldwide impacted by neurodegenerative diseases,” said Gary Romano, M.D., Ph.D., Chief Medical Officer at Alector. "With a robust dataset from the INVOKE-2 trial, we plan to further explore TREM2 biology. We extend our deepest gratitude to the dedicated investigators, patients and caregivers who made this important trial possible. We plan to share the results of the trial with the scientific community in the near future in the hopes of contributing to the understanding of AD pathophysiology and advancing effective therapeutics for this terrible disease.” Based upon the results, Alector is stopping the long-term extension study. Alector remains committed to advancing its mechanistically broad and genetically validated drug candidates for the treatment of neurodegenerative diseases. At the core of this effort are the company's progranulin-elevating programs, latozinemab and AL101/GSK4527226, developed in collaboration with GSK. Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in frontotemporal dementia with a progranulin gene mutation is expected in late 2025 or early 2026. PROGRESS-AD, a global Phase 2 clinical trial evaluating AL101/GSK4527226 in early AD, has reached more than one-third of its target enrollment of 282 participants. Alector is also advancing its preclinical candidates aimed at a broad and diverse range of protein and enzyme targets. In addition to advancing its pipeline, the company is continuing to develop its proprietary and versatile blood-brain barrier technology platform, Alector Brain Carrier (ABC). ABC aims to enhance the delivery of therapeutic antibodies, proteins and enzymes, achieve deeper penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. To align resources with these strategic priorities, Alector is reducing its workforce by approximately 17%. By focusing on organizational goals, Alector continues to build upon its core strength in developing novel therapies for neurodegenerative diseases, with the potential to deliver transformative value for patients. As of September 30, 2024, Alector has $457.2 million in cash, cash equivalents, and investments, which the company continues to expect will provide runway through 2026. Alector plans to provide guidance for 2025 during its fourth-quarter and full-year earnings conference call. About INVOKE-2 INVOKE-2 (Clinicaltrials.gov identifier NCT04592874), was a randomized, double-blind, placebo-controlled, dose-ranging, multi-center Phase 2 clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD). The trial, conducted at multiple sites across 11 countries, utilized a common close design with up to 96 weeks of randomized treatment, and all participants remained on their assigned regimen until the last participant completed 48 weeks of treatment. This design provided the opportunity to capture more observations for the primary analysis, with data collected at 48, 72, and 96 weeks. Patients were randomized to three dose regimens of AL002, 15mg/kg IV/q4w, 40mg/kg IV/q4w, 60mg/kg IV/q4w, or placebo. About Alector Alector is a clinical-stage biotechnology company that has pioneered immuno-neurology. The company has discovered and is developing a portfolio of mechanistically broad and genetically validated product candidates, including antibodies, protein and enzyme replacement therapies, for neurodegenerative diseases. Supported by biomarkers, Alector's product candidates seek to treat a range of indications, including frontotemporal dementia, Alzheimer's disease, and Parkinson's disease. Alector is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its next-generation product candidates and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com . Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding our business plans, workforce reduction, business strategy, product candidates, planned and ongoing preclinical studies and clinical trials, expected milestones, and expectations of our collaborations. Such statements are subject to numerous risks and uncertainties, including but not limited to risks and uncertainties as set forth in Alector's Quarterly Report on Form 10-Q filed on November 6, 2024, with the Securities and Exchange Commission ("SEC”), as well as the other documents Alector files from time to time with the SEC. These documents contain and identify important factors that could cause the actual results for Alector to differ materially from those contained in Alector's forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alector specifically disclaims any obligation to update any forward-looking statement, except as required by law. Alector Contacts: Alector Katie Hogan 202-549-0557 [email protected] 1AB (media) Dan Budwick 973-271-6085 [email protected] Argot Partners (investors) Laura Perry 212-600-1902 [email protected]Don't write the obituary of the lunch hour just yet6 yen to php 。

Shlomo Nehama Steps Down as Chairman of the Board of Ellomay Capital Ltd.

The Fine Gael leader was asked about the controversy in the first question posed during the second and final TV leaders’ debate of Ireland’s General Election campaign. Mr Harris apologised over the weekend for his handling of the discussion with Charlotte Fallon while canvassing in Kanturk in Co Cork on Friday evening. The Taoiseach was accused of dismissing concerns that Ms Fallon raised about Government support for the disability sector during the exchange filmed by RTE in a supermarket. Mr Harris rang Ms Fallon on Saturday and said he unreservedly apologised for the way he treated her, however focus has since shifted to Fine Gael’s interactions with the national broadcaster about the social media video. At the outset of Tuesday’s TV debate, co-host Miriam O’Callaghan directly asked the Fine Gael leader whether a member of his party contacted RTE to ask for the clip to be taken down. “I have no knowledge of that whatsoever, because this clip was entirely appropriate,” said Mr Harris. “It was a very important moment on the campaign. “And RTE and indeed many media outlets have been with me throughout the campaign, covering many interactions that I’ve had with many, many people right across this country.” The Taoiseach said the approach by his team member was part of the “normal contact that happens between party politics and broadcasters on a daily basis”. Mr Harris’s partner-in-government in the last coalition, Fianna Fail leader Micheal Martin, said he was not aware of the approach to RTE by Fine Gael. “I didn’t realise this had happened,” he said. “I think Simon has given his explanation to it. I’m not sure it’s as normal or as usual. I just get on with it every day. But, again, I think, you know, I’m not au fait with the details behind all of this, or the background to it. “The video didn’t come down, and it was seen by many, many people. “And I think it illustrates that out there, there are a lot of people suffering in our society. “Notwithstanding the progress we’ve made as a country, a lot of people are facing a lot of individual challenges, and our job as public representatives and as leaders in travelling the country is to listen to people, hear their cases, to understand the challenges that they are going through in their lives. “And when we go about in election campaigns, we have to open up ourselves to criticism and to people calling us to account.” Sinn Fein leader Mary Lou McDonald had earlier in the day described reports of the Fine Gael approach to RTE as “chilling”. However, at the start of the debate, she was asked about a media-focused issue related to her own party, namely the controversial manifesto proposal for an independent expert review of RTE’s objectivity in its coverage of the war in Gaza and other international conflicts. Mr Harris previously branded the proposal a “dog whistle to conspiracy theorists” while Mr Martin said it was a “dangerous departure”. Ms McDonald defended the idea during the RTE Prime Time debate on Tuesday. “Politics and politicians should not try to influence editorial decisions or try and have clips taken down because they are inconvenient to them,” she said. “There has to be distance, there has to be objectivity. But I would say I am struck by the very defensive reaction from some to this (the review proposal). “The BBC, for example, a peer review looked at their coverage on migration. Politicians didn’t put their hands on it, and rightly so. “I think in a world where we have to rely on quality information, especially from the national broadcaster, which is in receipt of very substantial public funding, that has to be the gold standard of reliability. I think peer reviews like that are healthy.”US expected to send £1 billion in weapons to Ukraine before Trump takes office

Monster Beverage Corp. stock falls Tuesday, underperforms marketNone

Shares of Super Micro Computer rose sharply Monday, as the data center technology AI powerhouse appeared to recover from recent heavy losses. SMCI stock surged 15.9% to close at 38.41, as the stock reclaimed its 50-day average. It was a clear a sign that the company has rebounded from setbacks that sent SMCI stock crashing, one analyst said. "I think they're back," Ray Wang, founder and principal analyst at Constellation Research, told Investor's Business Daily. SMCI Stock: Investors Get Spooked Supermicro stock started crashing over the past months on a series of news events that spooked the data center technology company's investors. The shares fell sharply in late August after the company announced that following a prominent short-seller's allegations accusing SMCI of accounting irregularities. Then SMCI stock plummeted in late October when the company . The company then reeled from speculation that from the Nasdaq. After that, things started looking up. The stock rallied in mid-November after Supermicro . The stock has been climbing since then, posting gains in six of the last seven trading days. 'They've Been So Battered Down' "They've been so battered down," Wang told IBD. "I think the accounting issues are resolved so people are less worried." The accounting worries hit what has been one of the highflier in the AI craze. Supermicro quickly emerged as one of the main beneficiaries of the AI juggernaut, together with companies like Nvidia, Microsoft and Google. "If you're just trying to figure out derivatives on AI and Nvidia growth, Supermicro is going to be one of the winners," Wang said. "If you're a portfolio manager and you're looking at AI stocks to go after, you're going to want to look at Supermicro." Supermicro's woes . Dell stock rallied during times when bad news hit SMCI. Make no mistake, Super Micro isn't just Dell's competitor — it's "the" competitor for AI servers, Melius Research analyst Ben Reitzes told clients in a Nov. 4 note. "Boy was it one of the big winners" when Super Micro's auditor resigned he said. The impact of Supermicro's recent problems on Dell should become clearer Tuesday when the tech giant reports quarterly results.A new frame is coming to Warframe with the game’s upcoming 1999 expansion: Cyte-09. Cyte-09 will be Warframe’s 59th frame and the latest after Koumei, but until recently, not much has been known about him. But that’s changing as developer Digital Extremes releases more information. We don’t know exactly when Warframe: 1999 is coming, although it’s set for December, but there is a lot to look forward to, like Cyte-09, the Technocyte Coda , new weapons, new modes, new areas, and more. Keep reading to learn everything we know about Warframe’s next frame, Cyte-09. What are Cyte-09’s abilities in Warframe? The concept for Cyte-09 is a stealthy sniper Warframe, and that’s been known for a while, but we’ve only learned recently what his abilities actually do, which is as follows: Sneak : Plant an antenna that projects a forward wave scan. Detected enemies take increased weak point damage and become visible through walls. Weapons gain punchthrough. Resupply : Throw two elemental ammo packs that instantly refill the active weapon’s magazine and grant the weapon an additional instance of a selected elemental damage type and status effect. Reload clears the effect. Sniper rifles gain extra damage. Evade : Jump backwards and become invisible for a short duration. Weak point kills extend the duration and heal Cyte-09. Neutralize : Summon the Neutralizer, Cyte-09’s exalted sniper rifle. Bullets ricochet off weak points to seek out other nearby weak points. Alt fire lobs a cold grenade that completely freezes enemies. The big question when it comes to Cyte-09 is how his exalted sniper rifle will work. It’s unclear not only how powerful it will be but also exactly what its mechanics are and how they might synergize with Cyte-09’s other abilities. We don’t have these answers yet, but Warframe: 1999 isn’t too far off. What does the Warframe community think about Cyte-09? In general, spirits are high. Many community members are excited to see another stealth frame get added to the game, the prospect of an exalted sniper rifle many find fresh and interesting, and Cyte-09’s kit seems to appeal to many Warframe fans. However, some do have concerns. Considering the Warframe meta is so strongly focused on AoE damage potential, particularly when it comes to weapons, some worry that a sniper rifle might not be able to keep up in higher-level content. Some already anticipate replacing Cyte-09’s sniper rifle ability with something else. Others wonder how ‘bullets ricocheting off weak points to seek out other weak points’ will work in the context of Cyte-09’s overall kit and if that ricochet power will be enough to take down tough enemies with ease or not. Of course, this is all speculation in the here and now.

NoneHow Moeller IP empowers brand protection against counterfeiting in Latin America

Fans of The Batman franchise will have to wait even longer for the most expected sequel. ET Year-end Special Reads Two sectors that rose on India's business horizon in 2024 2025 outlook: Is it time for cautious optimism or rekindling animal spirits? 2024: Govt moves ahead with simultaneous polls plan; India holds largest democratic exercise The latest update from Deadline confirms that The Batman Part II has been delayed once again, now set to premiere on October 1, 2027. This marks a delay of an entire year from its originally expected release, extending the wait for eager audiences who were hoping for an earlier return to Gotham City. Director Matt Reeves Returns Matt Reeves, who directed the first film, will once again helm the sequel, continuing the dark and gritty tale of Bruce Wayne's transformation into the iconic vigilante. Robert Pattinson will reprise his role as the troubled young billionaire who adopts the Batman persona after the traumatic loss of his parents, as per a report by Collider. Artificial Intelligence(AI) Java Programming with ChatGPT: Learn using Generative AI By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Basics of Generative AI: Unveiling Tomorrows Innovations By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Generative AI for Dynamic Java Web Applications with ChatGPT By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Mastering C++ Fundamentals with Generative AI: A Hands-On By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Master in Python Language Quickly Using the ChatGPT Open AI By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Performance Marketing for eCommerce Brands By - Zafer Mukeri, Founder- Inara Marketers View Program Office Productivity Zero to Hero in Microsoft Excel: Complete Excel guide 2024 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance A2Z Of Money By - elearnmarkets, Financial Education by StockEdge View Program Marketing Modern Marketing Masterclass by Seth Godin By - Seth Godin, Former dot com Business Executive and Best Selling Author View Program Astrology Vastu Shastra Course By - Sachenkumar Rai, Vastu Shashtri View Program Strategy Succession Planning Masterclass By - Nigel Penny, Global Strategy Advisor: NSP Strategy Facilitation Ltd. View Program Data Science SQL for Data Science along with Data Analytics and Data Visualization By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) AI and Analytics based Business Strategy By - Tanusree De, Managing Director- Accenture Technology Lead, Trustworthy AI Center of Excellence: ATCI View Program Web Development A Comprehensive ASP.NET Core MVC 6 Project Guide for 2024 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Digital Marketing Masterclass by Pam Moore By - Pam Moore, Digital Transformation and Social Media Expert View Program Artificial Intelligence(AI) AI-Powered Python Mastery with Tabnine: Boost Your Coding Skills By - Metla Sudha Sekhar, IT Specialist and Developer View Program Office Productivity Mastering Microsoft Office: Word, Excel, PowerPoint, and 365 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Digital marketing - Wordpress Website Development By - Shraddha Somani, Digital Marketing Trainer, Consultant, Strategiest and Subject Matter expert View Program Office Productivity Mastering Google Sheets: Unleash the Power of Excel and Advance Analysis By - Metla Sudha Sekhar, IT Specialist and Developer View Program Web Development Mastering Full Stack Development: From Frontend to Backend Excellence By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance Financial Literacy i.e Lets Crack the Billionaire Code By - CA Rahul Gupta, CA with 10+ years of experience and Accounting Educator View Program Data Science SQL Server Bootcamp 2024: Transform from Beginner to Pro By - Metla Sudha Sekhar, IT Specialist and Developer View Program As Gotham City continues to grapple with corruption and chaos, The Batman Part II promises to delve deeper into the city's dark underbelly, although specific plot details remain tightly under wraps. The Expanding Gotham Universe While the delay of The Batman Part II may be disappointing to fans, Warner Bros. remains committed to expanding the Gotham universe. The Penguin, a spin-off television series focusing on Colin Farrell's character Oz Cobblepot, has recently concluded its first season, garnering strong viewership numbers for HBO and Max. Additionally, the studio is working on another version of Batman within the newly established DC Universe. The Brave and the Bold, a film featuring a different iteration of the Dark Knight, is in development under the direction of Andy Muschietti. However, the release date for this project has yet to be announced, and Muschietti has confirmed that the film has also been delayed. The Future of Gotham Despite the delay, excitement for The Batman Part II remains high. The extended wait gives fans time to reflect on the first film and speculate about what new challenges Bruce Wayne will face in the sequel. The Batman (2022) is currently streaming on Max, while The Batman Part II is now scheduled to hit theaters on October 1, 2027. FAQs Who will be Joker in Batman 2? Barry Keoghan remains tight-lipped about reprising his role as the Joker in The Batman - Part II . Keoghan made his debut as the Clown Prince of Crime with a brief but memorable appearance in The Batman . Who killed Batman's parents? In Batman's origin story, Joe Chill is the criminal responsible for the tragic murder of Bruce Wayne's parents, Dr. Thomas Wayne and Martha Wayne. (You can now subscribe to our Economic Times WhatsApp channel )LISBON, Portugal (AP) — The goals are flying in again for Arsenal — and it just happens to coincide with the return from injury of Martin Odegaard. Make that eight goals in two games since the international break for Arsenal after its 5-1 hammering of Sporting Lisbon in the Champions League on Tuesday, tying the English team’s heaviest ever away win in the competition. Odegaard is back in Arsenal’s team after missing two months with an ankle injury . In that time, Mikel Arteta’s attack stuttered, with a 2-0 loss to Bournemouth and a 1-0 defeat at Newcastle dropping the Gunners well off the pace in the Premier League. There was also a 0-0 draw at Atalanta in the Champions League as well as a 1-0 loss to Inter Milan last month, when Odegaard made his comeback from injury as an 89th-minute substitute. Since then, Arsenal hasn’t lost and the goals have returned. After a 3-0 win over Nottingham Forest on Saturday came the cruise in Lisbon — and Odegaard was at the heart of everything as Sporting’s unbeaten start to the season came to an end. “He’s an unbelievable player,” Arsenal winger Bukayo Saka said of Odegaard. “The day he returned, there was a big smile on my face. You can see the chemistry we have. I hope he stays fit for the rest of the season.” Odegaard was involved in the build-up to Arsenal’s first two goals against Sporting — scored by Gabriel Martinelli and Kai Havertz — and was fouled to win the penalty converted by Saka in the 65th to restore Arsenal’s three-goal lead at 4-1. Odegaard was seen flexing his leg after that but continued untroubled and was substituted in the 78th minute. The last thing Arteta would want now is another injury to Odegaard as Arsenal attempts to reel in first-place Liverpool in the Premier League. Liverpool is already nine points ahead of fourth-place Arsenal after 12 games. AP soccer: https://apnews.com/hub/soccerOn a rare two-game skid, No. 24 Arizona faces Davidson

None

No. 24 Arizona is coming off consecutive defeats for the first time in the Tommy Lloyd era when it faces undefeated Davidson on Wednesday to begin the Battle 4 Atlantis in Paradise Island, Bahamas. Arizona (2-2) lost at Wisconsin 103-88 on Nov. 15 and followed that with a home loss against Duke 69-55 on Friday. The Wildcats have dropped 15 spots in the Associated Press Top 25 poll in two weeks. Arizona's record is .500 this early in a season for the first time since it was 3-3 to start the 2017-18 schedule. "I've got work to do, so let's get to work," said Lloyd, in his fourth year as Arizona's head coach. "Let's see where we're at in a month, and if we're still struggling, you know what I'll do? I still got work to do, but I'm gonna get to it." Arizona shot 39.6 percent from the field against Duke, and just 26.1 percent (6 of 23) from 3-point range. The Wildcats were outrebounded by 43-30 and their 15 turnovers led to 19 points. Jaden Bradley led Arizona with 18 points and KJ Lewis added 12. Preseason All-American Caleb Love had eight points on 3-of-13 shooting from the field, including 1-of-9 from 3-point range. Arizona made only one field goal in the last 5:39 as Duke pulled away after its lead was trimmed to six points. "We didn't play great," Lloyd said. "Now we need to take a step back and figure out why. Are there some schematic problems? Are there some problems with how our personnel is kind of put together? "We got to figure out what our certainties are, and the things we have to have, and then over the course of the next couple of days, if there's adjustments we need to make, we need to figure out what those are." Davidson is 4-0 after a 15-17 record last season, in which it lost its last six games to put an end to postseason hopes. A 93-66 win over visiting VMI on Friday followed a 91-85 win at Bowling Green and 76-70 victory over visiting East Tennessee State. The two wins by 10 points or fewer are important because Davidson was 6-12 in such games last season. It was 4-11 in games decided by five points or fewer. "The goal (is) to get better," Davidson head coach Matt McKillop said after the season opener. "We talk about fighting to win every possession. I think we had to figure out what that really felt like with the lights on." Davidson made 13 shots from 3-point range in the win over VMI. Reed Bailey had 23 points, eight rebounds and six assists. Bobby Durkin added 19 points, including 17 of them and a career-best five 3-pointers in the first half. Bailey leads Davidson in scoring (19 points per game) and rebounding (7.8). Durkin is shooting 57.9 percent (22 of 38) from the field and 54.2 percent (13 of 24) from 3-point range. By contrast, Arizona's Love is shooting 32 percent (16 of 50) from the field and 21.4 percent (6 of 28) from beyond the arc. Bradley leads Arizona with 15.5 points per game. He is shooting 50 percent (24 of 48) from the field and is 35.7 percent (5 of 14) from 3-point range. --Field Level Media

MOUNT PLEASANT – After she was handed the keys to the town of Mount Pleasant, retired tennis star Shelby Rogers had one question. “What can I use these for?” Rogers asked Mount Pleasant Mayor Will Haynie. Lowcountry teams sweep state tennis titles The question was ironic, because it was the town of Mount Pleasant that was one key to helping Rogers unlock her tennis potential years ago. “It’s where I started,” Rogers said as kids practiced at the Mount Pleasant Tennis Complex on Thursday afternoon. “And if I wasn’t from here, I would not have had the career I’ve had.” Rogers, who is 32 and retired this year at the U.S. Open in August, was honored by her hometown on Nov. 21, and will be inducted into the S.C. Tennis Hall of Fame this weekend in Hilton Head. Haynie declared Nov. 23 “Shelby Rogers Day” in Mount Pleasant, and said that Rogers will act as the grand marshal of the Mount Pleasant Christmas parade. Rogers also will have a court named after at the tennis complex on Whipple Road. Charleston's Emma Navarro wins, Shelby Rogers heads for prime time at US Open “I spent a lot of time here at Whipple Road, running around the courts and the fields, playing tag,” Rogers said. “The memories are flooding back tonight, and having everyone here to share this moment is really special.” One person on hand was tennis coach Bryan Minton, who gave Rogers her first lesson when she was seven years old at the Family Circle Tennis Center on Daniel Island. “The first day I saw here, I told the tennis director, “This girl has some potential, do you mind if I take her under my wing?” Minton said. “So yeah, it was literally the first day I saw her.” Born in Mount Pleasant, Rogers turned pro when she was 17 after a dominant junior career. She won more than $5.6 million in her pro career, rising to a high of No. 30 on the WTA Tour in August of 2022. Rogers reached the quarterfinals of the U.S. Open and the French Open. She earned a reputation as a giant-killer on the WTA Tour, with victories over stars such as Serena Williams, Simona Halep, Ash Barty, Petra Kvitova and Elena Rybakina. Tributes for Charleston tennis star Shelby Rogers after retirement news Growing up, Rogers famously worked as a ballkid at the Family Circle Cup on Daniel Island and played in the tournament (now the Credit One Charleston Open) 13 times. She's also been an analyst on TV broadcasts, and plans to be on hand for the Charleston Open next year.